[ASAP] Kinetic Steering of Amyloid Formation and Polymorphism by Canagliflozin, a Type-2 Diabetes Drug 🔗 Access full article via Journal of the American Chemical SocietyShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
